Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16

A water‐soluble and stable camptothecin derivative, CPT‐11, was found to possess a strong antitumor activity against various murine tumors. In the present study, CPT‐11 was tested against ten human gastrointestinal cancer xenograft lines carried by nude mice. CPT‐11 was very effective against nine x...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of surgical oncology 1993-12, Vol.54 (4), p.211-215
Hauptverfasser:	Nagai, Satoshi, Yamauchi, Masaji, Satta, Tetsuya, Kodera, Yasuhiro, Kondou, Ken, Akiyaya, Seiji, Ito, Katsuki, Takagi, Hiroshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Animals Antineoplastic agents Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Camptothecin - analogs & derivatives Camptothecin - therapeutic use Chemotherapy CPT-11 Etoposide - therapeutic use Female gastrointestinal cancer Gastrointestinal Neoplasms - drug therapy Humans Irinotecan Male Medical sciences Mice Mice, Nude Neoplasm Transplantation Pharmacology. Drug treatments Transplantation, Heterologous Tumor Cells, Cultured VP-16 xenograft
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	215
container_issue	4
container_start_page	211
container_title	Journal of surgical oncology
container_volume	54
creator	Nagai, Satoshi Yamauchi, Masaji Satta, Tetsuya Kodera, Yasuhiro Kondou, Ken Akiyaya, Seiji Ito, Katsuki Takagi, Hiroshi
description	A water‐soluble and stable camptothecin derivative, CPT‐11, was found to possess a strong antitumor activity against various murine tumors. In the present study, CPT‐11 was tested against ten human gastrointestinal cancer xenograft lines carried by nude mice. CPT‐11 was very effective against nine xenograft lines, with the exception of one xenograft. On the other hand, VP‐16 was ineffective against all these xenograft lines. Therefore, CPT‐11 is expected to be clinically more effective against gastrointestinal cancer than the topo II targeting agent. © 1993 Wiley‐Liss, Inc.
doi_str_mv	10.1002/jso.2930540404
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76110733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76110733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4074-77738f0f5e535849741fdab569a3d347e7eadf11f60736ebb93597d4465bf073</originalsourceid><addsrcrecordid>eNqFkEtvEzEURq0KVELplh2SF4jdBDt-jZco0BRU9SGidml5Zq4blxlPaztK8-_rKlEQK-SFJd_zfb46CH2kZEoJmX19SON0phkRnJRzhCaUaFlpous3aFKAWcWVJu_Q-5QeCCFaS36MjuuZEETpCYJFHDd5hX1Y-cZnPwY8OrxaDzbge5tyHH3IkLIPtsetDS1E_AxhvI_WZdz7AAk3W5wj2DxAyHjjS9v8ellRim3o8O11ReUH9NbZPsHp_j5By7Mfy_l5dXG1-Dn_dlG1nCheKaVY7YgTIJiouVacus42QmrLOsYVKLCdo9RJopiEptFMaNVxLkXjytMJ-rKrfYzj07psbQafWuh7G2BcJ6MkpQVjBZzuwDaOKUVw5jH6wcatocS8ajVFq_mrtQQ-7ZvXzQDdAd97LPPP-7lNre1dLKZ8OmCsrgWv64LpHbbxPWz_86n59fvqnxWqXdanDM-HrI1_jFRMCXN3uTC3Z-d3i-83zCj2Akn7nyM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76110733</pqid></control><display><type>article</type><title>Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Nagai, Satoshi ; Yamauchi, Masaji ; Satta, Tetsuya ; Kodera, Yasuhiro ; Kondou, Ken ; Akiyaya, Seiji ; Ito, Katsuki ; Takagi, Hiroshi</creator><creatorcontrib>Nagai, Satoshi ; Yamauchi, Masaji ; Satta, Tetsuya ; Kodera, Yasuhiro ; Kondou, Ken ; Akiyaya, Seiji ; Ito, Katsuki ; Takagi, Hiroshi</creatorcontrib><description>A water‐soluble and stable camptothecin derivative, CPT‐11, was found to possess a strong antitumor activity against various murine tumors. In the present study, CPT‐11 was tested against ten human gastrointestinal cancer xenograft lines carried by nude mice. CPT‐11 was very effective against nine xenograft lines, with the exception of one xenograft. On the other hand, VP‐16 was ineffective against all these xenograft lines. Therefore, CPT‐11 is expected to be clinically more effective against gastrointestinal cancer than the topo II targeting agent. © 1993 Wiley‐Liss, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.2930540404</identifier><identifier>PMID: 8255079</identifier><identifier>CODEN: JSONAU</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Animals ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - therapeutic use ; Biological and medical sciences ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; Chemotherapy ; CPT-11 ; Etoposide - therapeutic use ; Female ; gastrointestinal cancer ; Gastrointestinal Neoplasms - drug therapy ; Humans ; Irinotecan ; Male ; Medical sciences ; Mice ; Mice, Nude ; Neoplasm Transplantation ; Pharmacology. Drug treatments ; Transplantation, Heterologous ; Tumor Cells, Cultured ; VP-16 ; xenograft</subject><ispartof>Journal of surgical oncology, 1993-12, Vol.54 (4), p.211-215</ispartof><rights>Copyright © 1993 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4074-77738f0f5e535849741fdab569a3d347e7eadf11f60736ebb93597d4465bf073</citedby><cites>FETCH-LOGICAL-c4074-77738f0f5e535849741fdab569a3d347e7eadf11f60736ebb93597d4465bf073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.2930540404$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.2930540404$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3885488$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8255079$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagai, Satoshi</creatorcontrib><creatorcontrib>Yamauchi, Masaji</creatorcontrib><creatorcontrib>Satta, Tetsuya</creatorcontrib><creatorcontrib>Kodera, Yasuhiro</creatorcontrib><creatorcontrib>Kondou, Ken</creatorcontrib><creatorcontrib>Akiyaya, Seiji</creatorcontrib><creatorcontrib>Ito, Katsuki</creatorcontrib><creatorcontrib>Takagi, Hiroshi</creatorcontrib><title>Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>A water‐soluble and stable camptothecin derivative, CPT‐11, was found to possess a strong antitumor activity against various murine tumors. In the present study, CPT‐11 was tested against ten human gastrointestinal cancer xenograft lines carried by nude mice. CPT‐11 was very effective against nine xenograft lines, with the exception of one xenograft. On the other hand, VP‐16 was ineffective against all these xenograft lines. Therefore, CPT‐11 is expected to be clinically more effective against gastrointestinal cancer than the topo II targeting agent. © 1993 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>Chemotherapy</subject><subject>CPT-11</subject><subject>Etoposide - therapeutic use</subject><subject>Female</subject><subject>gastrointestinal cancer</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Irinotecan</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Neoplasm Transplantation</subject><subject>Pharmacology. Drug treatments</subject><subject>Transplantation, Heterologous</subject><subject>Tumor Cells, Cultured</subject><subject>VP-16</subject><subject>xenograft</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtvEzEURq0KVELplh2SF4jdBDt-jZco0BRU9SGidml5Zq4blxlPaztK8-_rKlEQK-SFJd_zfb46CH2kZEoJmX19SON0phkRnJRzhCaUaFlpous3aFKAWcWVJu_Q-5QeCCFaS36MjuuZEETpCYJFHDd5hX1Y-cZnPwY8OrxaDzbge5tyHH3IkLIPtsetDS1E_AxhvI_WZdz7AAk3W5wj2DxAyHjjS9v8ellRim3o8O11ReUH9NbZPsHp_j5By7Mfy_l5dXG1-Dn_dlG1nCheKaVY7YgTIJiouVacus42QmrLOsYVKLCdo9RJopiEptFMaNVxLkXjytMJ-rKrfYzj07psbQafWuh7G2BcJ6MkpQVjBZzuwDaOKUVw5jH6wcatocS8ajVFq_mrtQQ-7ZvXzQDdAd97LPPP-7lNre1dLKZ8OmCsrgWv64LpHbbxPWz_86n59fvqnxWqXdanDM-HrI1_jFRMCXN3uTC3Z-d3i-83zCj2Akn7nyM</recordid><startdate>199312</startdate><enddate>199312</enddate><creator>Nagai, Satoshi</creator><creator>Yamauchi, Masaji</creator><creator>Satta, Tetsuya</creator><creator>Kodera, Yasuhiro</creator><creator>Kondou, Ken</creator><creator>Akiyaya, Seiji</creator><creator>Ito, Katsuki</creator><creator>Takagi, Hiroshi</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199312</creationdate><title>Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16</title><author>Nagai, Satoshi ; Yamauchi, Masaji ; Satta, Tetsuya ; Kodera, Yasuhiro ; Kondou, Ken ; Akiyaya, Seiji ; Ito, Katsuki ; Takagi, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4074-77738f0f5e535849741fdab569a3d347e7eadf11f60736ebb93597d4465bf073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>Chemotherapy</topic><topic>CPT-11</topic><topic>Etoposide - therapeutic use</topic><topic>Female</topic><topic>gastrointestinal cancer</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Irinotecan</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Neoplasm Transplantation</topic><topic>Pharmacology. Drug treatments</topic><topic>Transplantation, Heterologous</topic><topic>Tumor Cells, Cultured</topic><topic>VP-16</topic><topic>xenograft</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagai, Satoshi</creatorcontrib><creatorcontrib>Yamauchi, Masaji</creatorcontrib><creatorcontrib>Satta, Tetsuya</creatorcontrib><creatorcontrib>Kodera, Yasuhiro</creatorcontrib><creatorcontrib>Kondou, Ken</creatorcontrib><creatorcontrib>Akiyaya, Seiji</creatorcontrib><creatorcontrib>Ito, Katsuki</creatorcontrib><creatorcontrib>Takagi, Hiroshi</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagai, Satoshi</au><au>Yamauchi, Masaji</au><au>Satta, Tetsuya</au><au>Kodera, Yasuhiro</au><au>Kondou, Ken</au><au>Akiyaya, Seiji</au><au>Ito, Katsuki</au><au>Takagi, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>1993-12</date><risdate>1993</risdate><volume>54</volume><issue>4</issue><spage>211</spage><epage>215</epage><pages>211-215</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><coden>JSONAU</coden><abstract>A water‐soluble and stable camptothecin derivative, CPT‐11, was found to possess a strong antitumor activity against various murine tumors. In the present study, CPT‐11 was tested against ten human gastrointestinal cancer xenograft lines carried by nude mice. CPT‐11 was very effective against nine xenograft lines, with the exception of one xenograft. On the other hand, VP‐16 was ineffective against all these xenograft lines. Therefore, CPT‐11 is expected to be clinically more effective against gastrointestinal cancer than the topo II targeting agent. © 1993 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8255079</pmid><doi>10.1002/jso.2930540404</doi><tpages>5</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0022-4790
ispartof	Journal of surgical oncology, 1993-12, Vol.54 (4), p.211-215
issn	0022-4790 1096-9098
language	eng
recordid	cdi_proquest_miscellaneous_76110733
source	Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects	Adult Animals Antineoplastic agents Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Camptothecin - analogs & derivatives Camptothecin - therapeutic use Chemotherapy CPT-11 Etoposide - therapeutic use Female gastrointestinal cancer Gastrointestinal Neoplasms - drug therapy Humans Irinotecan Male Medical sciences Mice Mice, Nude Neoplasm Transplantation Pharmacology. Drug treatments Transplantation, Heterologous Tumor Cells, Cultured VP-16 xenograft
title	Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20inhibition%20of%20human%20gastrointestinal%20cancer%20xenograft%20lines%20by%20treatment%20with%20CPT-11%20and%20VP-16&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Nagai,%20Satoshi&rft.date=1993-12&rft.volume=54&rft.issue=4&rft.spage=211&rft.epage=215&rft.pages=211-215&rft.issn=0022-4790&rft.eissn=1096-9098&rft.coden=JSONAU&rft_id=info:doi/10.1002/jso.2930540404&rft_dat=%3Cproquest_cross%3E76110733%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76110733&rft_id=info:pmid/8255079&rfr_iscdi=true